Atrakt
Atrakt Uses, Dosage, Side Effects, Food Interaction and all others data.
Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Trade Name | Atrakt |
Generic | Atracurium besylate |
Atracurium besylate Other Names | Atracurium besilate, Atracurium besylate, Atracurium dibesylate, Besilate d'atracurium, Besilato de atracurio |
Type | Injection |
Formula | C65H82N2O18S2 |
Weight | Average: 1243.49 Monoisotopic: 1242.500406156 |
Groups | Approved |
Therapeutic Class | Non depolarizing muscle relaxants |
Manufacturer | Gland Pharma Limited |
Available Country | India |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Atracurium is used for endotracheal intubation, facilitate mechanical ventilation in intensive care, muscle relaxant in general anaesthesia.
Atrakt is also used to associated treatment for these conditions: Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy
How Atrakt works
Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Dosage
Atrakt dosage
Adult andChild (>1 month): Initially, 300-600 mcg/kg as bolus IV, with subsequent doses of 100-200 mcg/kg by IV every 15-25 min or 5-10 mcg/kg/min by infusion in prolonged procedures. Higher infusion rate may be used in patients undergoing controlled ventilation in intensive care.
Side Effects
Skin flush, erythema, pruritus, urticaria, wheezing, increased bronchial secretions, bronchospasm, cyanosis, angioedema, CV effects (e.g. bradycardia); wheals and erythema at inj site. Potentially Fatal: Anaphylaxis.
Toxicity
Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
Precaution
Patient with CV disease, burn injury, asthma; conditions which may antagonise neuromuscular blockade (e.g. resp alkalosis, hypercalcaemia, demyelinating lesions, peripheral neuropathies, denervation, muscle trauma); conditions which may potentiate neuromuscular blockade (e.g. electrolyte abnormalities, neuromuscular diseases, metabolic acidosis, resp acidosis, Eaton-Lambert syndrome, myasthenia gravis). Pregnancy and lactation.
Interaction
Enhanced neuromuscular blocking effect w/ general anaesth (e.g. enflurane, isoflurane, halothane), certain antibiotics (e.g. aminoglycosides, polymyxins), lithium, Mg salts, procainamide, quinidine.
Food Interaction
No interactions found.Half Life
The elimination half-life is approximately 20 minutes.
Pregnancy & Breastfeeding use
Pregnancy Category C: Teratogenic Effects. Atrakt has been shown to be potentially teratogenic in rabbits when given in doses up to approximately one-half the human dose. There are no adequate and well-controlled studies in pregnant women. Atracurium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Contraindication
Atracurium is contraindicated in patients known to be hypersensitive to atracurium, cisatracurium or benzenesulfonic acid. In common with all the other neuromuscular blocking agents, atracurium besilate paralyses the respiratory muscles as well as other skeletal muscles but has no effect on consciousness.
Acute Overdose
Stimulation of histamine release, CV effects especiall hypotension
Storage Condition
Store between 2-8° C. Do not freeze.
Innovators Monograph
You find simplified version here Atrakt
Atrakt contains Atracurium besylate see full prescribing information from innovator Atrakt Monograph, Atrakt MSDS, Atrakt FDA label